Zhang M, Di Martino JS, Bowman RL, Campbell NR, Baksh SC, Simon-Vermot T, Kim IS, Haldeman P, Mondal C, Yong-Gonzales V et al..  2018.  Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.. Cancer Discov. 8(8):1006-1025.

McBride MJ, Pulice JL, Beird HC, Ingram DR, D'Avino AR, Shern JF, Charville GW, Hornick JL, Nakayama RT, Garcia-Rivera EM et al..  2018.  The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.. Cancer Cell. 33(6):1128-1141.e7.

Rao TDharma, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J et al..  2017.  Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.. ACS Chem Biol. 12(8):2085-2096.

Herting CJ, Chen Z, Pitter KL, Szulzewsky F, Kaffes I, Kaluzova M, Park JC, Cimino PJ, Brennan C, Wang B et al..  2017.  Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.. Glia. 65(12):1914-1926.

Zhang Y, Yu J, Grachtchouk V, Qin T, Lumeng CN, Sartor MA, Koenig RJ.  2017.  Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.. Oncotarget. 8(4):5761-5773.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, S Kang P, Shankaran V et al..  2017.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.. J Clin Invest. 127(8):2930-2940.

Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M et al..  2017.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.. Nature. 546(7658):431-435.

Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS.  2017.  Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.. J Nucl Med. 58(9):1386-1394.

Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S et al..  2016.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.. Genome Biol. 17(1):174.

Wang D, Narula N, Azzopardi S, Smith RS, Nasar A, Altorki NK, Mittal V, Somwar R, Stiles BM, Du Y-CNancy.  2016.  Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma.. Oncotarget. 7(26):39957-39969.

Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D et al..  2016.  Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.. Cancer Immunol Res. 4(11):936-947.

Azzopardi S, Pang S, Klimstra DS, Du Y-CNancy.  2016.  p53 and p16/p19 Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells.. Neoplasia. 18(10):610-617.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A et al..  2016.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.. Genome Biol. 17(1):231.

Ross JB, Huh D, Noble LB, Tavazoie SF.  2015.  Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer.. Nat Cell Biol. 17(5):651-64.

Furlow PW, Zhang S, T Soong D, Halberg N, Goodarzi H, Mangrum C, Y Wu G, Elemento O, Tavazoie SF.  2015.  Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival.. Nat Cell Biol. 17(7):943-52.

McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T.  2014.  p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.. Proc Natl Acad Sci U S A. 111(16):E1600-9.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E et al..  2013.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.. Science. 340(6132):626-30.

Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S et al..  2013.  Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma.. Mol Cell. 50(2):185-99.

Pencheva N, Tran H, Buss C, Huh D, Drobnjak M, Busam K, Tavazoie SF.  2012.  Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis.. Cell. 151(5):1068-82.

Chung YRock, Schatoff E, Abdel-Wahab O.  2012.  Epigenetic alterations in hematopoietic malignancies.. Int J Hematol. 96(4):413-27.

Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J et al..  2007.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.. Cancer Cell. 11(2):147-60.

Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA.  2002.  Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.. Oncogene. 21(1):108-18.